Literature DB >> 10928184

Postoperative radiation therapy for stage IB-IIB carcinoma of the cervix with poor prognostic factors.

T Uno1, H Ito, J Itami, S Yasuda, K Isobe, R Hara, T Sato, S Minoura, N Shigematsu, A Kubo.   

Abstract

BACKGROUND: To investigate failure pattern and to evaluate the prognostic impact of lymph node metastasis in patients with cervical cancer treated with postoperative adjuvant pelvic irradiation.
MATERIALS AND METHODS: Ninety-eight patients with FIGO IB to IIB cervical cancer were treated with radical hysterectomy, bilateral pelvic lymphadenectomy and postoperative radiation therapy. All the patients had at least one of the following pathologic risk factors for pelvic recurrence; 1) positive margins, 2) positive pelvic lymph nodes other than common iliac node, 3) deep stromal invasion more than 50% or parametrial invasion.
RESULTS: The 5-year overall survival (OAS) rate for the entire patient group was 82%. Causes of the first failure were pelvic recurrence in 5 cases and distant metastasis in 15 cases. Fifteen of the 47 patients with positive pelvic lymph nodes developed distant metastasis, whereas distant metastasis was noted in only 1 of 51 patients without lymph node metastasis. The 5-year OAS rates for patients with and without pelvic lymph node metastasis were 76% and 89%, respectively (p = 0.018).
CONCLUSION: Despite receiving postoperative pelvic irradiation, apparently lower survival was observed for node positive patients.

Entities:  

Mesh:

Year:  2000        PMID: 10928184

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

Review 1.  Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancer.

Authors:  Noriaki Sakuragi
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

2.  Prognostic significance of positive lymph node number in early cervical cancer.

Authors:  Jung-Woo Park; Jong Woon Bae
Journal:  Mol Clin Oncol       Date:  2016-03-30

Review 3.  Postoperative radiation therapy for carcinoma of the uterine cervix.

Authors:  Takashi Uno; Koichi Isobe; Seiji Yamamoto; Tetsuya Kawata; Hisao Ito
Journal:  Radiat Med       Date:  2006-02

Review 4.  Recent progress in the treatment and prevention of cancer-related lymphedema.

Authors:  Simona F Shaitelman; Kate D Cromwell; John C Rasmussen; Nicole L Stout; Jane M Armer; Bonnie B Lasinski; Janice N Cormier
Journal:  CA Cancer J Clin       Date:  2014-11-19       Impact factor: 508.702

5.  Evaluation of outcome and prognostic factors in 739 patients with uterine cervix carcinoma: a single institution experience.

Authors:  Fatma Teke; Adnan Yöney; Memik Teke; Gültekin Adanaş; Zuhat Urakçı; Gül Türkcü; Bekir Eren; Ali İnal; Mustafa Ünsal
Journal:  Contemp Oncol (Pozn)       Date:  2015-05-13

6.  Postoperative external beam irradiation with and without brachytherapy in pelvic node-positive IB1-IIA2 cervical cancer patients: a retrospective clinical study.

Authors:  Lei Li; XinXin Kou; XiaoJie Feng; MingChuan Zhang; HongTu Chao; LiYing Wang
Journal:  Radiat Oncol       Date:  2015-09-17       Impact factor: 3.481

7.  Development and Validation of a Nomogram for Predicting Postoperative Distant Metastasis in Patients with Cervical Cancer.

Authors:  Weihong Zeng; Lishan Huang; Haihong Lin; Ru Pan; Haochang Liu; Jizhong Wen; Ye Liang; Haikun Yang
Journal:  Med Sci Monit       Date:  2022-04-12

8.  The influence of number of high risk factors on clinical outcomes in patients with early-stage cervical cancer after radical hysterectomy and adjuvant chemoradiation.

Authors:  Soyi Lim; Seok-Ho Lee; Kwang Beom Lee; Chan-Yong Park
Journal:  Obstet Gynecol Sci       Date:  2016-05-13

9.  Prognostic factors affecting survival and recurrence in patients with early cervical squamous cell cancer following radical hysterectomy.

Authors:  Dan Li; Xiaoxian Xu; Dingding Yan; Shuhui Yuan; Juan Ni; Hanmei Lou
Journal:  J Int Med Res       Date:  2019-12-31       Impact factor: 1.671

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.